Merck KGaA, Darmstadt, Germany, and GSK have formed a global alliance to jointly develop and commercialize bintrafusp alfa (M7824), an investigational bifunctional fusion protein designed to target both TGF-β and PD-L1. Together, we are inspired by curiosity, science, and, most importantly, patients, combining a creative approach with our relentless drive to transform cancer research.
Together, as leaders of this novel immunotherapy class, we aim to drive innovation in cancer care. Jointly, we are working to accelerate bintrafusp alfa clinical development programs to improve patient opportunity. Bintrafusp alfa is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers.